Skip to main content

Premenstrual Dysphoric Disorder

2
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
paroxetinePhase 4
Ergomed
ErgomedUK - Guildford
1 program
1
SepranolonePhase 21 trial
Active Trials
NCT03697265Completed475Est. Oct 2020
UCB Pharma
UCB PharmaBelgium - Brussels
1 program
LevetiracetamN/A1 trial
Active Trials
NCT00518570Completed7Est. Oct 2006
Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
1 program
paroxetinePHASE_41 trial
Active Trials
NCT00516113Completed24Est. Nov 2002

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Novo Nordiskparoxetine
ErgomedSepranolone
UCB PharmaLevetiracetam

Clinical Trials (3)

Total enrollment: 506 patients across 3 trials

NCT00516113Novo Nordiskparoxetine

A Placebo-Controlled Study to Investigate the Onset of Action of Paroxetine in Premenstrual Dysphoria

Start: Oct 2000Est. completion: Nov 200224 patients
Phase 4Completed
NCT03697265ErgomedSepranolone

A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)

Start: Apr 2018Est. completion: Oct 2020475 patients
Phase 2Completed
NCT00518570UCB PharmaLevetiracetam

Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)

Start: Nov 2003Est. completion: Oct 20067 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.